search
Back to results

Romidepsin in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors

Primary Purpose

Gastrinoma, Glucagonoma, Insulinoma

Status
Terminated
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
romidepsin
laboratory biomarker analysis
Sponsored by
National Cancer Institute (NCI)
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Gastrinoma

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Histologically confirmed carcinoid tumor or islet cell neuroendocrine tumor Well- or moderately-differentiated tumor Metastatic and/or locally advanced disease Measurable disease Unidimensionally measurable lesion at least 20 mm by conventional techniques OR at least 10 mm by spiral CT scan Lesions in a previously irradiated area are not considered measurable No truly non-measurable lesions, including the following: Bone lesions Leptomeningeal disease Ascites Pleural or pericardial effusion Lymphangitis cutis/pulmonis Abdominal masses not confirmed and followed by imaging Cystic lesions Ineligible for standard treatment Performance status - ECOG 0-1 At least 6 months WBC >= 3,000/mm^3 Absolute neutrophil count >= 1,500/mm^3 Platelet count >= 100,000/mm^3 Bilirubin =< 1.5 mg/dL AST and ALT =< 2.5 times upper limit of normal Creatinine =< 1.5 mg/dL No New York Heart Association class III or IV congestive heart failure No myocardial infarction within the past year No uncontrolled dysrhythmias No poorly controlled angina No serious ventricular arrhythmia, defined as ventricular tachycardia or ventricular fibrillation >= 3 beats in a row No left ventricular hypertrophy by EKG No other significant cardiac disease QTc < 500 msec LVEF > 40% by resting MUGA No prior allergic reaction attributed to compounds of similar chemical or biological composition to study drug No ongoing or active infection No psychiatric illness or social situation that would preclude study compliance No other concurrent uncontrolled illness Not pregnant or nursing Negative pregnancy test Fertile patients must use effective contraception More than 4 weeks since prior immunotherapy (e.g., interferon alfa) More than 4 weeks since prior chemotherapy More than 12 weeks since prior hepatic artery chemoembolization unless liver lesions are not the only indicator lesions No prior FR901228 (depsipeptide) No more than 1 prior systemic chemotherapy regimen for carcinoid or islet cell tumor (other than hepatic artery chemoembolization) More than 4 weeks since prior oral or IV steroids (first 16 patients only) Concurrent long-acting octreotide allowed at standard doses if dose has been stable for the past 12 weeks Concurrent subcutaneous octreotide for breakthrough use for symptomatic relief allowed No concurrent systemic steroids (first 16 patients only) More than 4 weeks since prior radiotherapy More than 4 weeks since prior investigational tumor-specific therapy No other prior histone deacetylase inhibitors (e.g., valproic acid) No concurrent hydrochlorothiazide No concurrent combination antiretroviral therapy for HIV-positive patients No other concurrent investigational or commercial agents or therapies for the malignancy

Sites / Locations

  • Ohio State University Medical Center

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Treatment (romidepsin)

Arm Description

Patients receive romidepsin IV over 4 hours on days 1, 8, and 15. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients achieving CR receive 2 additional courses beyond CR.

Outcomes

Primary Outcome Measures

Objective response rate
Frequency of response will be estimated with a 95% confidence interval.

Secondary Outcome Measures

Incidence of toxicity

Full Information

First Posted
June 10, 2004
Last Updated
June 3, 2013
Sponsor
National Cancer Institute (NCI)
search

1. Study Identification

Unique Protocol Identification Number
NCT00084461
Brief Title
Romidepsin in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors
Official Title
Phase II Study of Depsipeptide in Metastatic Neuroendocrine Tumors
Study Type
Interventional

2. Study Status

Record Verification Date
June 2013
Overall Recruitment Status
Terminated
Study Start Date
March 2004 (undefined)
Primary Completion Date
October 2004 (Actual)
Study Completion Date
undefined (undefined)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
National Cancer Institute (NCI)

4. Oversight

5. Study Description

Brief Summary
Phase II trial to study the effectiveness of romidepsin in treating patients who have locally advanced or metastatic neuroendocrine tumors. Drugs used in chemotherapy, such as romidepsin, work in different ways to stop tumor cells from dividing so they stop growing or die.
Detailed Description
PRIMARY OBJECTIVES: I. Determine objective response rate in patients with locally advanced or metastatic neuroendocrine tumors treated with FR901288 (romidepsin). SECONDARY OBJECTIVES: I. Determine the toxicity of this drug in these patients. II. To measure serum tumor markers (pancreastatin, gastrin, pancreatic polypeptide, glucagon, substance-P, neurotensin, calcitonin, somatostatin, vasoactive intestinal peptide, gastrin releasing polypeptide, ACTH) depending on the tumor type pre-, during-, and post-treatment. III. To perform a nuclear medicine functional imaging scan (octreoscan) to evaluate the disease status pre-, during-, and post-treatment. IV. To perform histone acetylation assay in cytospins from peripheral blood mononuclear cells (PBMCs) to correlate with disease response and with immunologic parameters. V. To quantify gene expression by Real Time PCR of type 1 and type 2 cytokines, co-stimulatory molecules, and adhesion molecules in PBMCs obtained from the pre-, during-, and post-treatment blood samples. VI. To perform a multicolor flow cytometric analysis on fresh blood to assess activation of lymphocyte subsets and presence of co-stimulatory and adhesion molecules. VII. To perform in vitro functional assays for innate as well as antigen-specific T cell immune responses in PBMCs obtained from the pre-, during-, and post-treatment blood samples. OUTLINE: Patients receive romidepsin IV over 4 hours on days 1, 8, and 15. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients achieving complete remission (CR) receive 2 additional courses beyond CR. Patients are followed at 2-4 weeks.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Gastrinoma, Glucagonoma, Insulinoma, Metastatic Gastrointestinal Carcinoid Tumor, Pancreatic Polypeptide Tumor, Pulmonary Carcinoid Tumor, Recurrent Gastrointestinal Carcinoid Tumor, Recurrent Islet Cell Carcinoma, Regional Gastrointestinal Carcinoid Tumor, Somatostatinoma

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
25 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Treatment (romidepsin)
Arm Type
Experimental
Arm Description
Patients receive romidepsin IV over 4 hours on days 1, 8, and 15. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients achieving CR receive 2 additional courses beyond CR.
Intervention Type
Drug
Intervention Name(s)
romidepsin
Other Intervention Name(s)
FK228, FR901228, Istodax
Intervention Description
Given IV
Intervention Type
Other
Intervention Name(s)
laboratory biomarker analysis
Intervention Description
Correlative studies
Primary Outcome Measure Information:
Title
Objective response rate
Description
Frequency of response will be estimated with a 95% confidence interval.
Time Frame
Up to 4 weeks
Secondary Outcome Measure Information:
Title
Incidence of toxicity
Time Frame
Up to 4 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Histologically confirmed carcinoid tumor or islet cell neuroendocrine tumor Well- or moderately-differentiated tumor Metastatic and/or locally advanced disease Measurable disease Unidimensionally measurable lesion at least 20 mm by conventional techniques OR at least 10 mm by spiral CT scan Lesions in a previously irradiated area are not considered measurable No truly non-measurable lesions, including the following: Bone lesions Leptomeningeal disease Ascites Pleural or pericardial effusion Lymphangitis cutis/pulmonis Abdominal masses not confirmed and followed by imaging Cystic lesions Ineligible for standard treatment Performance status - ECOG 0-1 At least 6 months WBC >= 3,000/mm^3 Absolute neutrophil count >= 1,500/mm^3 Platelet count >= 100,000/mm^3 Bilirubin =< 1.5 mg/dL AST and ALT =< 2.5 times upper limit of normal Creatinine =< 1.5 mg/dL No New York Heart Association class III or IV congestive heart failure No myocardial infarction within the past year No uncontrolled dysrhythmias No poorly controlled angina No serious ventricular arrhythmia, defined as ventricular tachycardia or ventricular fibrillation >= 3 beats in a row No left ventricular hypertrophy by EKG No other significant cardiac disease QTc < 500 msec LVEF > 40% by resting MUGA No prior allergic reaction attributed to compounds of similar chemical or biological composition to study drug No ongoing or active infection No psychiatric illness or social situation that would preclude study compliance No other concurrent uncontrolled illness Not pregnant or nursing Negative pregnancy test Fertile patients must use effective contraception More than 4 weeks since prior immunotherapy (e.g., interferon alfa) More than 4 weeks since prior chemotherapy More than 12 weeks since prior hepatic artery chemoembolization unless liver lesions are not the only indicator lesions No prior FR901228 (depsipeptide) No more than 1 prior systemic chemotherapy regimen for carcinoid or islet cell tumor (other than hepatic artery chemoembolization) More than 4 weeks since prior oral or IV steroids (first 16 patients only) Concurrent long-acting octreotide allowed at standard doses if dose has been stable for the past 12 weeks Concurrent subcutaneous octreotide for breakthrough use for symptomatic relief allowed No concurrent systemic steroids (first 16 patients only) More than 4 weeks since prior radiotherapy More than 4 weeks since prior investigational tumor-specific therapy No other prior histone deacetylase inhibitors (e.g., valproic acid) No concurrent hydrochlorothiazide No concurrent combination antiretroviral therapy for HIV-positive patients No other concurrent investigational or commercial agents or therapies for the malignancy
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Manisha Shah
Organizational Affiliation
Ohio State University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Ohio State University Medical Center
City
Columbus
State/Province
Ohio
ZIP/Postal Code
43210
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Romidepsin in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors

We'll reach out to this number within 24 hrs